AU Patent

AU2015292425B2 — 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof

Assigned to Beta Pharma Inc · Expires 2018-12-20 · 7y expired

What this patent protects

Indazole compounds of formula (I) as cyclin-dependent kinase (CDK) and cellproliferation inhibitors, and therapeutic uses and methods of preparation thereof, are disclosed. These compounds, and pharmaceutically acceptable salts, solvates, prodrugs, and pharmaceutical compositions…

USPTO Abstract

Indazole compounds of formula (I) as cyclin-dependent kinase (CDK) and cellproliferation inhibitors, and therapeutic uses and methods of preparation thereof, are disclosed. These compounds, and pharmaceutically acceptable salts, solvates, prodrugs, and pharmaceutical compositions thereof, are useful for treating diseases and disorders associated with activity of cyclin-dependent kinases, in particular CDK4/6, including but not limited to various cancers and inflammation-related diseases or conditions:

Drugs covered by this patent

Patent Metadata

Patent number
AU2015292425B2
Jurisdiction
AU
Classification
—
Expires
2018-12-20
Drug substance claim
No
Drug product claim
No
Assignee
Beta Pharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.